Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis

This study explores the efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease (IBD) through a meta-analysis.

A comprehensive search encompassed randomised controlled trials examining the efficacy of etrolizumab in the treatment of IBD in PubMed, Embase, the Cochrane Library and Web of Science, with a search cut-off date of 1 December 2023. Quality assessment was based on the Cochrane Manual's risk of bias assessment, while Stata 15 undertook the data analysis.